Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Hoepner

Showing results (21-30 of 129) with videos related to

Pageof 13
Sort By:
Therapeutic Advances in Neurological Disorders|November 12, 2015
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatmentSimon Faissner, Robert Hoepner, Carsten Lukas, et al.
Frontiers in Neurology|September 21, 2017
Insight into Metabolic <sup>1</sup>H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain LesionsRuth Schneider, Barbara Bellenberg, Robert Hoepner, et al.
Frontiers in Pharmacology|July 3, 2023
The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in DataAnke Salmen, Stefanie Marti, Andreas G F Hoepner, et al.
International Review of Neurobiology|August 29, 2022
Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD)Lara Diem, Helly Hammer, Robert Hoepner, et al.
Brain and Behavior|August 23, 2017
Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activityAndrei Miclea, Marius Miclea, Maximilian Pistor, et al.
JAMA Neurology|June 20, 2013
Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumabChristos Krogias, Robert Hoepner, Andre Müller, et al.
Epilepsy & Behavior : E&B|July 24, 2012
Symptoms and course of intoxication with mesuximide--a case reportRobert Hoepner, Theodor W May, Bernhard Rambeck, et al.
European Journal of Neurology|November 10, 2025
Measures of Comorbidities and Frailty in Multiple Sclerosis-Systematic Review on Evidence and Applicability of Utilized Scoring Systems in Clinical Routine and Real-World DataMarie Louise Aicher, Fabian Föttinger, Robert Hoepner, et al.
Frontiers in Neurology|February 7, 2025
Chronic fatigue and headache in post-COVID-19 syndrome: a radiological and clinical evaluationGonçalo G Almeida, Saide Alkan, Robert Hoepner, et al.
Leukemia Research Reports|June 13, 2018
1,25-OH<sub>2</sub> vitamin D<sub>3</sub> and AKT-inhibition increase glucocorticoid induced apoptosis in a model of T-cell acute lymphoblastic leukemia (ALL)Maximilian Pistor, Lisa Schrewe, Steffen Haupeltshofer, et al.
Pageof 13

Showing results (21-30 of 129) with videos related to

Sort By:
Pageof 13
Therapeutic Advances in Neurological Disorders|November 12, 2015
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatmentSimon Faissner, Robert Hoepner, Carsten Lukas, et al.
Frontiers in Neurology|September 21, 2017
Insight into Metabolic <sup>1</sup>H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain LesionsRuth Schneider, Barbara Bellenberg, Robert Hoepner, et al.
Frontiers in Pharmacology|July 3, 2023
The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in DataAnke Salmen, Stefanie Marti, Andreas G F Hoepner, et al.
International Review of Neurobiology|August 29, 2022
Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD)Lara Diem, Helly Hammer, Robert Hoepner, et al.
Brain and Behavior|August 23, 2017
Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activityAndrei Miclea, Marius Miclea, Maximilian Pistor, et al.
JAMA Neurology|June 20, 2013
Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumabChristos Krogias, Robert Hoepner, Andre Müller, et al.
Epilepsy & Behavior : E&B|July 24, 2012
Symptoms and course of intoxication with mesuximide--a case reportRobert Hoepner, Theodor W May, Bernhard Rambeck, et al.
European Journal of Neurology|November 10, 2025
Measures of Comorbidities and Frailty in Multiple Sclerosis-Systematic Review on Evidence and Applicability of Utilized Scoring Systems in Clinical Routine and Real-World DataMarie Louise Aicher, Fabian Föttinger, Robert Hoepner, et al.
Frontiers in Neurology|February 7, 2025
Chronic fatigue and headache in post-COVID-19 syndrome: a radiological and clinical evaluationGonçalo G Almeida, Saide Alkan, Robert Hoepner, et al.
Leukemia Research Reports|June 13, 2018
1,25-OH<sub>2</sub> vitamin D<sub>3</sub> and AKT-inhibition increase glucocorticoid induced apoptosis in a model of T-cell acute lymphoblastic leukemia (ALL)Maximilian Pistor, Lisa Schrewe, Steffen Haupeltshofer, et al.
Pageof 13